Naphazoline

Pupils may become enlarged with use; temporary light sensitivity may occur. Brief tingling after administration may occur. Disease-related concerns:

Use naphazoline with caution in patients with cardiovascular abnormalities or hypertension.

Use naphazoline with caution in patients with diabetes mellitus.

Use naphazoline with caution in patients with hyperthyroidism.

Use naphazoline with caution in patients with local infection or injury. Concurrent drug therapy issues:

Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Dosage form specific issues:

May contain benzalkonium chloride which may be absorbed by soft contact lenses. Other warnings/precautions:

For ophthalmic use only. Inadvertent contamination of multiple-dose ophthalmic solutions, has caused bacterial keratitis; avoid contamination.

When used for self-medication (OTC), patients with narrow-angle glaucoma or prostatic hyperplasia should consult health care provider before use. Do not use >72 hours; overuse may cause more eye redness. Notify healthcare provider if eye pain or vision changes occur or if redness or irritation gets worse or lasts >72 hours. Do not use with contact lenses. Do not use if solution changes color or becomes cloudy.

Accidental ingestion by children of over-the-counter (OTC) imidazoline-derivative eye drops and nasal sprays may result in serious harm. Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization have been reported in children ≤5 years of age who had ingested even small amounts (eg, 1 to 2 mL). Contact a poison control center and seek emergency medical care immediately for accidental ingestion (FDA Drug Safety Communication 2012).